浸润性乳腺癌组织HER2与Ki67联合表达与蒽环类化疗药物的疗效及预后相关
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

江苏省卫生健康委科研项目(Z2020005);南京医科大学科技发展基金(2017NJMUZD107)


Expression level of HER2/Ki67 is association with efficacy of anthracycline chemotherapeutic drugs and clinical prognosis in invasive breast cancer
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨浸润性乳腺癌组织中HER2与Ki67的表达与蒽环类化疗药物疗效及临床预后的相关性。方法:数据库预测HER2基因在浸润性乳腺癌组织中的表达情况及与Ki67的关联性分析;利用Nanostring nCounter技术检测53例浸润性乳腺癌石蜡包埋组织标本中HER2的mRNA表达情况,并分析蒽环类化疗药物的疗效;收集2008—2012年浸润性乳腺癌的组织蜡块222例,免疫组织化学方法检测HER2与Ki67的蛋白表达情况,并结合临床病理资料、化疗疗效及预后情况进行相关性分析。结果:GEPIA数据库分析显示HER2 mRNA在浸润性乳腺癌组织中的表达和Ki67的表达具有相关性;Nanostring nCounter技术检测53例浸润性乳腺癌组织中HER2 mRNA的表达水平,阳性16/53(30.19%),阴性为37/53(69.81%),HER2阳性患者中3例化疗有效(18.80%),13例无效(81.20%),HER2阴性患者中19例(51.35%)有效,18例(48.65%)无效;222例浸润性乳腺癌临床病理资料结果显示,HER2-/Ki67+浸润性乳腺癌患者有较好的化疗疗效和预后。结论:HER2阴性浸润性乳腺癌患者中,Ki67高表达预示有较好的化疗疗效,HER2-/Ki67+的浸润性乳腺癌患者预示有较好的生存期。

    Abstract:

    Objective:This study aims to investigate the expression level of HER2/Ki67 is association with efficacy of anthracycline chemotherapeutic drugs and clinical prognosis in invasive breast cancer. Methods:The expression level of HER2 and Ki67 in invasive breast cancer were predicted by database. The mRNA expression of HER2 in 53 cases of invasive breast cancer FFPE was detected by Nanostring nCounter technique,and the efficacy of anthracycline chemotherapeutic drugs was analyzed. Total 222 cases of invasive breast cancer tissue samples from 2008 to 2012 were collected to analyze the protein expression level of HER2 and Ki67,and the correlation analysis was conducted based on the clinicopathological data and the chemotherapy efficacy of the patients. Results:GEPIA database analysis showed that there was a correlation between the HER2 mRNA and Ki67 mRNA. The expression level of HER2 mRNA in 53 cases of invasive breast cancer was detected by Nanostring nCounter. The positive rate was 16/53(30.19%)and the negative rate was 37/53(69.81%). Among the HER2 positive patients,chemotherapy was effective in 3 cases(18.80%)and ineffective in 13 cases(81.20%). In the HER2 negative patients,chemotherapy was effective in 19 cases(51.35%)and ineffective in 18 cases(48.65%). The results of the clinicopathological data of 222 cases of invasive breast cancer showed that the invasive breast cancer patients with HER2-/KI67+ predicted better chemotherapy efficacy and prognosis. Conclusion:In patients with HER2-negative invasive breast cancer,the high expression of Ki67 indicates a better effect of chemotherapy,while the patients with HER2-/Ki67+ predict a better survival time.

    参考文献
    相似文献
    引证文献
引用本文

赵伟志,赵 薇,杨小兵,赵 坤.浸润性乳腺癌组织HER2与Ki67联合表达与蒽环类化疗药物的疗效及预后相关[J].南京医科大学学报(自然科学版),2021,(6):873-878

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2020-09-16
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2021-06-26
  • 出版日期:
通知关闭
郑重声明